- New knowledge about common molecular, cellular and pathophysiological mechanisms in DS, AD and PD.
- New molecular, neuroimaging and cognitive biomarkers across our target diseases.
- Bio-repositories (human samples and iPSCs) for further research.
- New molecular targets for common therapy for patients affected by DS, AD and PD.
HEROES will impact on clinical diagnosis, and also provide important information on biomarkers of dementia progression that will be valuable for prognosis and future clinical studies. In addition, HEROES will improve knowledge of common mechanisms and pathways of degeneration, which could help to identify new treatment strategies.